Polyelectrolyte-enrobed cancer cells in view of personalized immune-therapy
- Author
- Lien Lybaert (UGent) , Keun Ah Ryu, Riet De Rycke (UGent) , Alfred C Chon, Olivier De Wever (UGent) , Karim Vermaelen (UGent) , Aaron Esser-Kahn and Bruno De Geest (UGent)
- Organization
- Abstract
- Targeting the immune system with a personalized vaccine containing cues derived from the patient's malignancy might be a promising approach in the fight against cancer. It includes neo-antigens as well as nonmutated tumor antigens, preferentially leading to an immune response that is directed to a broader range of epitopes compared to strategies involving a single antigen. Here, this paper reports on an elegant method to encapsulate whole cancer cells into polyelectrolyte particles. Porous and nonaggregated microparticles containing dead cancer cells are obtained by admixing mannitol and live cancer cells with oppositely charged polyelectrolytes, dextran sulfate (anionic polysaccharide), and poly-l-arginine (cationic polypeptide) prior to atomization into a hot air stream. It shows that the polyelectrolyte-enrobed cancer cells, upon redispersion in phosphate buffered saline buffer, are stable and do not release cell proteins in the supernatant. In vitro experiments reveal that the particles are nontoxic and strongly increase uptake of cell lysate by dendritic cells. In vitro assessment of antigen presentation by dendritic cells reveal the potential of the polyelectrolyte-enrobed cancer cells as promotors of antigen cross-presentation. Finally, it is demonstrated that the immunogenicity can be enhanced by surface adsorption of a polymer-substituted TLR7-agonist.
- Keywords
- DENDRITIC CELLS, VACCINE DELIVERY, IMMUNOTHERAPY, MICROPARTICLES, NEOANTIGENS, FORMULATION, FACILE, dendritic cells, immunotherapy, microparticles, polyelectrolytes
Downloads
-
Lybaert et al-2017-Advanced Science.pdf
- full text
- |
- open access
- |
- |
- 1.96 MB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-8540462
- MLA
- Lybaert, Lien, et al. “Polyelectrolyte-Enrobed Cancer Cells in View of Personalized Immune-Therapy.” ADVANCED SCIENCE, vol. 4, no. 6, 2017, doi:10.1002/advs.201700050.
- APA
- Lybaert, L., Ryu, K. A., De Rycke, R., Chon, A. C., De Wever, O., Vermaelen, K., … De Geest, B. (2017). Polyelectrolyte-enrobed cancer cells in view of personalized immune-therapy. ADVANCED SCIENCE, 4(6). https://doi.org/10.1002/advs.201700050
- Chicago author-date
- Lybaert, Lien, Keun Ah Ryu, Riet De Rycke, Alfred C Chon, Olivier De Wever, Karim Vermaelen, Aaron Esser-Kahn, and Bruno De Geest. 2017. “Polyelectrolyte-Enrobed Cancer Cells in View of Personalized Immune-Therapy.” ADVANCED SCIENCE 4 (6). https://doi.org/10.1002/advs.201700050.
- Chicago author-date (all authors)
- Lybaert, Lien, Keun Ah Ryu, Riet De Rycke, Alfred C Chon, Olivier De Wever, Karim Vermaelen, Aaron Esser-Kahn, and Bruno De Geest. 2017. “Polyelectrolyte-Enrobed Cancer Cells in View of Personalized Immune-Therapy.” ADVANCED SCIENCE 4 (6). doi:10.1002/advs.201700050.
- Vancouver
- 1.Lybaert L, Ryu KA, De Rycke R, Chon AC, De Wever O, Vermaelen K, et al. Polyelectrolyte-enrobed cancer cells in view of personalized immune-therapy. ADVANCED SCIENCE. 2017;4(6).
- IEEE
- [1]L. Lybaert et al., “Polyelectrolyte-enrobed cancer cells in view of personalized immune-therapy,” ADVANCED SCIENCE, vol. 4, no. 6, 2017.
@article{8540462, abstract = {{Targeting the immune system with a personalized vaccine containing cues derived from the patient's malignancy might be a promising approach in the fight against cancer. It includes neo-antigens as well as nonmutated tumor antigens, preferentially leading to an immune response that is directed to a broader range of epitopes compared to strategies involving a single antigen. Here, this paper reports on an elegant method to encapsulate whole cancer cells into polyelectrolyte particles. Porous and nonaggregated microparticles containing dead cancer cells are obtained by admixing mannitol and live cancer cells with oppositely charged polyelectrolytes, dextran sulfate (anionic polysaccharide), and poly-l-arginine (cationic polypeptide) prior to atomization into a hot air stream. It shows that the polyelectrolyte-enrobed cancer cells, upon redispersion in phosphate buffered saline buffer, are stable and do not release cell proteins in the supernatant. In vitro experiments reveal that the particles are nontoxic and strongly increase uptake of cell lysate by dendritic cells. In vitro assessment of antigen presentation by dendritic cells reveal the potential of the polyelectrolyte-enrobed cancer cells as promotors of antigen cross-presentation. Finally, it is demonstrated that the immunogenicity can be enhanced by surface adsorption of a polymer-substituted TLR7-agonist.}}, articleno = {{1700050}}, author = {{Lybaert, Lien and Ryu, Keun Ah and De Rycke, Riet and Chon, Alfred C and De Wever, Olivier and Vermaelen, Karim and Esser-Kahn, Aaron and De Geest, Bruno}}, issn = {{2198-3844}}, journal = {{ADVANCED SCIENCE}}, keywords = {{DENDRITIC CELLS,VACCINE DELIVERY,IMMUNOTHERAPY,MICROPARTICLES,NEOANTIGENS,FORMULATION,FACILE,dendritic cells,immunotherapy,microparticles,polyelectrolytes}}, language = {{eng}}, number = {{6}}, pages = {{8}}, title = {{Polyelectrolyte-enrobed cancer cells in view of personalized immune-therapy}}, url = {{http://doi.org/10.1002/advs.201700050}}, volume = {{4}}, year = {{2017}}, }
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: